- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI files for approval of FS069
Molecular Biosystems of San Diego has filed a premarket approvalapplication for FS069, its second-generation ultrasound contrastagent. The submission involved clinical studies for cardiac function,focusing on enhancing endocardial border delineation. In
Molecular Biosystems of San Diego has filed a premarket approvalapplication for FS069, its second-generation ultrasound contrastagent. The submission involved clinical studies for cardiac function,focusing on enhancing endocardial border delineation. In addition,MBI hopes to get approval to use the agent for opacification ofthe left ventricular chamber. MBI has granted Mallinckrodt Medicallicenses to market FS069 in the U.S. and in a number of internationalmarkets (SCAN 12/18/96).
Can AI Enhance CT Detection of Incidental Extrapulmonary Abnormalities and Prediction of Mortality?
September 18th 2024Emphasizing multi-structure segmentation and feature extraction from chest CT scans, an emerging AI model demonstrated an approximately 70 percent AUC for predicting significant incidental extrapulmonary findings as well as two-year and 10-year all-cause mortality.
Comparing Digital Breast Tomosynthesis to Digital Mammography: What a Long-Term Study Reveals
September 17th 2024In a study involving over 272,000 breast cancer screening exams, digital breast tomosynthesis (DBT) had a higher breast cancer detection rate and a lower rate of advanced cancer presentation at the time of diagnosis in comparison to digital mammography.
Can Radiomics Enhance Differentiation of Intracranial Aneurysms on Computed Tomography Angiography?
September 17th 2024Radiomics models offered a pooled AUC of 86 percent for differentiating between ruptured and unruptured intracranial aneurysms, according to a recently published meta-analysis.
